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ABSTRACT
ObjectivesToinvestigatewhetherstatinsreduceallcause
mortality and major coronary and cerebrovascular events
inpeoplewithoutestablishedcardiovasculardiseasebut
with cardiovascular risk factors, and whether these
effects are similar in men and women, in young and older
(>65 years) people, and in people with diabetes mellitus.
Design Meta-analysis of randomised trials.
DatasourcesCochranecontrolledtrialsregister,Embase,
and Medline.
Data abstraction Two independent investigators
identified studies on the clinical effects of statins
comparedwithaplaceboorcontrolgroupandwithfollow-
up of at least one year, at least 80% or more participants
without established cardiovascular disease, and
outcome data on mortality and major cardiovascular
disease events. Heterogeneity was assessed using the Q
and I
2 statistics. Publication bias was assessed by visual
examinationoffunnelplotsandtheEggerregressiontest.
Results 10 trials enrolled a total of 70388 people, of
whom 23681 (34%) were women and 16078 (23%) had
diabetes mellitus. Mean follow-up was 4.1 years.
Treatment with statins significantly reduced the risk of all
causemortality(oddsratio0.88,95%confidenceinterval
0.81 to 0.96), major coronary events (0.70, 0.61 to0.81),
andmajorcerebrovascularevents(0.81,0.71to0.93).No
evidence of an increased risk of cancer was observed.
There was no significant heterogeneity of the treatment
effect in clinical subgroups.
Conclusion In patients without established
cardiovascular disease but with cardiovascular risk
factors, statin use was associated with significantly
improvedsurvivalandlargereductionsintheriskofmajor
cardiovascular events.
INTRODUCTION
Cardiovascular disease is the leading cause of death
and disability in the Western world and contributes
substantially to healthcare budgets.
1 Several clinical
trials and meta-analyses have shown the beneficial
effects of lipid lowering treatment using
hydroxylmethyl glutaryl coenzyme A reductase inhi-
bitors (statins) in reducing mortality and cardio-
vascular morbidity in patients with established
cardiovascular disease.
2-6 Statins therefore have a
place in the secondary prevention of cardiovascular
disease.
7-10
The use of statins in patients without established
cardiovascular disease (that is, primary prevention)
and at relatively low risk has important public health
implications. To date research has provided ambigu-
ous answers. In addition, the reliability of treatment in
older people (>65 years), women, and those with dia-
betes mellitus is uncertain, mainly because of a lack of
data or inconsistent findings within these clinically
definedgroups.
1112Mostmeta-analyseshavebeencar-
riedoutonpublishedtabulardataandfailedtoprovide
consistent answers on treatment effect in these
subgroups.
1314
We carried out a meta-analysis of randomised trials
that focused on primary prevention to determine
whether statins reduce all cause mortality and the inci-
denceofmajorcoronaryandcerebrovasculareventsin
people without established cardiovascular disease but
with cardiovascular risk factors. We also assessed
whether these effects differed by sex, age, and the pre-
sence of diabetes.
METHODS
We followed the quality of reporting of meta-analysis
guidelines.
15 We searched the Cochrane Central Reg-
ister of Controlled Trials, Medline (1990-November
2008), Embase (1980-November 2008), DARE, and
the ACP Journal Club for randomised clinical trials
that compared statins with a control group in people
without established cardiovascular disease but with
cardiovascular risk factors. We identified relevant stu-
dies using the MeSH terms “HMG-CoA reductase
inhibitor”,“atorvastatin”,“simvastatin”,“pravastatin”,
“fluvastatin”, “rosuvastatin”,o r“lovastatin”, and
“cardiovascular disease”, “coronary heart disease”,
“cerebrovascular disease”,o r“myocardial infarction”,
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“HDL” [high density lipoprotein], or “triglycerides”,
and primary prevention restricted to randomised con-
trolled trials or meta-analyses. In addition we exam-
ined the reference lists and related links of retrieved
articlesinPubMedtodetectstudiespotentiallyeligible
for inclusion.
Study selection
We included studies if they were randomised trials of
statins compared with controls (placebo, active con-
trol, or usual care), had a mean follow-up of at least
one year, reported on mortality or cardiovascular dis-
ease eventsas primary outcomes,and included at least
80% of people without established cardiovascular dis-
ease or reporteddata separately on a sole primarypre-
vention group and provided specific numbers for
patients and events in that group. Eight studies were
excluded that primarily investigated statin related
non-clinical and intermediate surrogate end points
such as changes in the thickness of the carotid intima
media and lipid levels that collectively contributed
fewer than 50 clinical events.
16-23 We also excluded
one study in patients with renal transplants because of
the specific nature of that population,
24 and three stu-
dies with design problems, fewer than 20 events over-
all, and insufficient follow-up.
25-27 Our study therefore
focused on people without established cardiovascular
disease but with cardiovascular risk factors.
Validity assessment
Oursearchidentified1230studies,ofwhich10fulfilled
our inclusion criteria.
w1-w10 Figure 1 summarises the
results of the search. We evaluated suitable trials for
concealment of treatment allocation, performance of
the analysis according to the intention to treat princi-
ple, and completeness of follow-up. The Jadad scale
was used to score study quality (range 0-5, higher
scores indicating better quality).
28 Study quality was
sufficient (≥4) for all included randomised clinical
trials.
Data abstraction
Fromeachstudytwoinvestigatorsseparatelyextracted
information on trial characteristics, patient data, out-
comemeasures,andstudyqualityusingastandardised
protocol and reporting document. Disagreements
were resolved by consensus.
Subgroup analysis
We searched the papers for data on clinically defined
subgroups.TheAntihypertensiveandLipid-Lowering
TreatmenttoPreventHeartAttackTrial(ALLHAT)
w7
presented data on our prespecified subgroups. The
other studies did not publish results stratified by age
(<65 or >65 years), sex, or diabetes. To obtain data
for these stratified groups we sent an electronic sheet
with data fields to the principal investigators of these
studies, requesting the number of events and number
of patients in the treatment and placebo groups. We
obtained data on subgroups for five trials.
w1-w3 w6 w8
Subgroup analyses were therefore done in six stu-
dies.
w1-w3 w6 w7 Not all end points were recorded in
these studies.
End points
The primary end point of our meta-analysis was all
cause mortality. Secondary end points were the com-
posite of major coronary events defined as death from
coronary heart disease and non-fatal myocardial
infarction,andthecompositeofmajorcerebrovascular
events defined as fatal and non-fatal stroke. We also
assessed death from coronary heart disease, non-fatal
myocardial infarction, revascularisations (percuta-
neouscoronaryinterventionorcoronaryarterybypass
graft),andcancer(fatalandnon-fatal).Theclinicalout-
comes evaluated in the subgroup analysis (data should
bereportedintwoormorestudies)wereallcausemor-
tality, major coronary events, major cerebrovascular
events, and cancer.
Quantitative data synthesis
For each trial we calculated the summary odds ratios
and95%confidenceintervalsfortheclinicaloutcomes.
We pooled studies using both fixed effect and random
effects models.
29 A random effects model makes the
assumption that individual studies are estimating dif-
ferent treatment effects. Our conclusions were drawn
from the results of the random effects model. We were
unabletoexcludeasmallproportionofsecondarypre-
vention patients from the West of Scotland Coronary
Prevention Study (1069/6595; WOSCOPS),
w9 ALL-
HAT (1470/10355),
w7 and the Anglo-Scandinavian
Cardiac Outcomes Trial lipid lowering arm (1906/
10305; ASCOT-LLA),
w10 and these therefore consti-
tute about 6% of our study population (4445/70388
).
30w7 w9 In a separate analysis we verified whether our
resultsremainedconsistentafterexclusionofthesestu-
dies. We also investigated whether our results differed
when we used the original study results from ASCOT
without extended follow-up.
30w10
Potentially relevant reports identified and screened for retrieval (n=1230)
Reports retrieved for more detailed evaluation (n=42)
Reports excluded on basis of title, abstract review
(clinical outcome not compatible, reviews, commentaries, letters to
editor, design papers, meta-analysis, or secondary prevention) (n=1188)
Potentially appropriate randomised controlled trials for meta-analysis (n=10)
Reports excluded from meta-analysis on basis of exclusion criteria:
follow-up <1 year, <80% primary prevention patients,
<50 deaths or cardiovascular disease outcomes, no controls (n=32)
Randomised controlled trials included in meta-analysis
with usable information for overall analysis (n=10)
Randomised controlled trials excluded from meta-analysis (n=0)
Fig 1 | Flow of article selection in trial
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analysisandsubgroupanalysisbyexaminingtheforest
plots and then calculating a Q statistic, which we com-
pared with a χ² distribution, and the I
2 index.
31 The Q
test indicates the statistical significance of the
homogeneity hypothesis and the I
2 index measures
the extent of the heterogeneity. We considered the
results for heterogeneity to be significant at P<0.10
(two sided). Publication bias was assessed for the
main end points by visually examining for funnel plot
Table 1 |Characteristics of included trials
Characteristic
WOSCOPS
1995w9
AFCAPS/
TexCAPS
1998w8
PROSPER*
2002w6
ALLHAT-LLT
2002w7
ASCOT-LLA
2003w10 HPS* 2003w5
CARDS
2004w4
ASPEN*
2006w3 MEGA 2006w2
JUPITER
2008w1
Target
population
Men with
hypercholes-
terolaemia (no
history of
myocardial
infarction)
People with
average or
below average
cholesterol
levels (without
atherosclerotic
cardiovascular
disease)
Elderly people
with
cardiovascular
risk factors
People with
hypertension,
moderate
hypercholes-
terolaemia,
and at least
one coronary
heart disease
risk factor
People with
hypertension,
average or
lower
cholesterol
levels, and at
least three
other risk
factors
People with
diabetes
People with
diabetes and
low density
lipoprotein
cholesterol (no
history of
cardiovascular
disease)
People with
diabetes and
low density
lipoprotein
cholesterol
levels below
guideline
targets
People with
hypercholes-
terolaemiaand
no history of
coronary heart
disease or
stroke
People without
vascular
disease, low
density
lipoprotein
cholesterol
<130mg/dl,and
high sensitivity
Cr e a c t i v e
protein >
2.0 mg/l
Design Randomised
double blind
placebo
controlled trial
Randomised
double blind
placebo
controlled trial
Randomised
double blind
placebo
controlled trial
Randomised
controlled trial
(control=usual
care)
Randomised
double blind
placebo
controlled trial
Randomised
double blind
placebo
controlled trial
Randomised
double blind
placebo
controlled trial
Randomised
double blind
placebo
controlled trial
Randomised
double blind
placebo
controlled trial
(control=diet)
Randomised
double blind
placebo
controlled trial
No of
participants
(statin/control)
6595 (3302/
3293)
6605 (3304/
3301)
3239 (1585/
1654)
10355 (5170/
5185)
10305 (5168/
5137)
2912 (1455/
1457)
2838 (1428/
1410)
1905 (959/
946)
7832 (3866/
3966)
17802 (8901/
8901)
Mean follow-up
(years)
4.9 5.2 3.2 4.8 5.5† 4.8 3.9† 4.0† 5.3 1.9†
Drug Pravastatin Lovastatin Pravastatin Pravastatin Atorvastatin Simvastatin Atorvastatin Atorvastatin Pravastatin Rosuvastatin
Dose (mg/day) 40 20-40 40 20-40 10 40 10 10 10 20 20
Mean age
(range) (years)
55.3 (45-64) 58 (45-73) 75 (70-82) 66.4 (51-81) 63.1 (40-79) NA (40-80) 61.5 (40-75) 60.5 (40-75) 58.3 (40-70) 66† (60-71)
Women (%) 0 15 58‡ 49 18.9 NA 32 38 68.4 37.9
With diabetes
(%)
1 3.8 12.2‡ 34.4 24.3 100 100 100 21 0
Current smoker
(%)
44 13 33.4‡ 23.3 33.2 NA 22 12 21 16
Hypertension
(%)
16 22 71.6‡ 89.9 80.3 NA 84 52 42 0
Mean body
mass index
26 26.8 27‡ 29.9 28.6 NA 28.7 28.9 23.8 28.4†
Mean systolic
blood pressure
(mm Hg)
136 138 156.6‡ 145 164.2 NA 144 133 132 134†
Mean diastolic
blood pressure
(mm Hg)
84 78 85.2‡ 84 95 NA 83 77.1 78.4 80†
Baseline lipid
levels (mmol/l)
(% change):
Total
cholesterol
7.0 (−20.0) 5.7 (−19.3) 5.7 (NA) 5.9 (−9.6) 5.5 (−18.2) NA 5.4 (−21.8) 5.0 (−19.8) 6.3 (−11.0) 4.8 (NA)
Low density
lipoprotein
cholesterol
5.0 (−26.0) 3.9 (−26.5) 3.8 (NA) 3.8 (−16.7) 3.4 (−27.6) NA 3.0 (−33.9) 3.0 (−30.5) 4.0 (−18.0) 2.8 (NA)
High density
lipoprotein
cholesterol
1.1 (5.0) 1.0 (4.8) 1.3 (NA) 1.2 (0.9) 1.3 (1.5) NA 1.4 (4.0) 1.2 (1.9) 1.5 (5.0) 1.3 (NA)
Triglycerides 1.8 (−12.0) 1.7 (−12.7) 1.5 (NA) 1.7 (0.0) 1.7 (−12.6) NA 2.0 (−15.9) 1.6 (−4.7) 1.4 (−7.0) 1.3 (NA)
NA=not available; WOSCOPS=West of Scotland Coronary Prevention Study; AFCAPS/TexCAPS=Air Force/Texas Coronary Atherosclerosis Prevention Study; PROSPER=Prospective Study of
Pravastatin in the Elderly at Risk; ALLHAT-LLT=Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ASCOT-LLA=Anglo-Scandinavian Cardiac Outcomes Trial—Lipid
Lowering Arm; HPS=Heart Protection Study (diabetic subgroup publication); CARDS=Collaborative Atorvastatin Diabetes Study; ASPEN=Atorvastatin Study for Prevention of Coronary Heart
Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus; MEGA=Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; JUPITER=Justification for the
Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin.
*Primary prevention subgroup data used.
†Median; in ASCOT-LLA data were from extended observations trial.
w10
‡Data from baseline characteristics publication of PROSPER.
33
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sion test to calculate two tailed P values.
32
RESULTS
Table 1 shows the characteristics of the 10 included
studies.
w1-w10 In total, 70388 participants were rando-
mised,ofwhom35138wereallocatedtostatintherapy
and 35250 to control. The number of participants in
the trials ranged from 1905 to 17802. The mean age
was63years(range55.3to75.0),andthemeanfollow-
upwas4.1years(range1.9to5.3).Thirtyfourpercent
ofparticipantswerewomenand23%haddiabetes.The
mean baseline low density lipoprotein cholesterol
level was 3.63 mmol/l. The mean reduction in levels
of total cholesterol was 17.1%, low density lipoprotein
cholesterolwas25.6%,andtriglyceridewas9.3%.High
density lipoprotein cholesterol increased by a mean
3.3%.
Mortality, coronary events, and cerebrovascular events
During a mean follow-up of 4.1 years 5.7% (1925/
33793) of participants died in the control group com-
paredwith5.1%(1725/33683) inthe statingroup.Sta-
tin therapy was therefore associated with a 12% risk
reductioninallcausemortalitycomparedwiththecon-
trol (odds ratio 0.88, 95% confidence interval 0.81 to
0.96; fig 2 and table 2). The annual rate for all cause
mortality with placebo in our study was 1.4% (fig 2).
Overall,5.4%(1266/23946)ofparticipantsinthe con-
trol group had a major coronary event compared with
4.1%(966/23823)inthestatingroup,a30%riskreduc-
tion (odds ratio 0.70, 95% confidence interval 0.61 to
0.81). The annual rate for major coronary events with
placebo in our study was 1.1% (fig 2). Overall, 2.3%
(767/33793) of participants in the control group had
a major cerebrovascular event compared with 1.9%
(627/33683) in the statin group, a 19% risk reduction
WOSCOPSw9
AFCAPS/TexCapsw8
PROSPER
w6
ALLHAT-LLT
w7
ASCOT-LLAw10
CARDS
w4
ASPENw3
MEGA
w2
JUPITER
w1
Total
  Q statistic P=0.20, I2=27.0%*
0.78 (0.60 to 1.01)
1.04 (0.76 to 1.43)
 0.98 (0.79 to 1.21)
0.99 (0.88 to 1.11)
0.85 (0.73 to 0.97)
0.72 (0.51 to 1.02)
1.06 (0.69 to 1.64)
0.71 (0.50 to 1.00)
0.80 (0.66 to 0.96) 
0.88 (0.81 to 0.96)
0.5 1 2
Study
All cause mortality
Favours
statin
Favours
control
No of patients/No of events
Odds ratio
(95% CI)
Odds ratio
(95% CI)
3302/106
3304/80
1585/163*
5170/631
5168/387
1428/61
959/44
3866/55
8901/198
33 683/1725
Statin
group
3293/135
3301/77
1654/174*
5185/641
5137/449
1410/82
946/41
3966/79
8901/247
33 793/1925
Control
group
0.68 (0.56 to 0.83)
0.61 (0.45 to 0.83)
0.90 (0.70 to 1.15)
0.90 (0.78 to 1.04)
0.64 (0.52 to 0.78)
 0.57 (0.41 to 0.79)
0.65 (0.44 to 0.97)
0.55 (0.33 to 0.91)
0.70 (0.61 to 0.81)
0.25 0.5 1 2
Study
Major coronary events
Favours
statin
Favours
control
No of patients/No of events
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Statin
group
Control
group
WOSCOPSw9
AFCAPS/TexCapsw8
PROSPER
w6
ALLHAT-LLT
w7
ASCOT-LLAw10
HPS
w5
CARDSw4
MEGA
w2
Total
  Q statistic P=0.02, I2=60.0%*
3293/248
3301/95*
1654/145
5185/421
5137/249
1457/NA
1410/65
3966/43†
23 946/1266
3302/174
3304/57*
1585/126
5170/380
5168/163
1455/NA
1428/43
3866/23†
23 823/966
0.25 0.5 1 2
WOSCOPS
w9
AFCAPS/TexCapsw8
PROSPER
w6
ALLHAT-LLT
w7
ASCOT-LLA
w10
CARDS
w4
ASPEN
w3
MEGA
w2
JUPITER
w1
Total
  Q statistic P=0.23, I2=24.0%*
0.90 (0.60 to 1.34)
  0.82 (0.40 to 1.67)
1.03 (0.72 to 1.47)
0.90 (0.75 to 1.09)
0.77 (0.63 to 0.95)
0.52 (0.31 to 0.90)
0.92 (0.54 to 1.56)
0.83 (0.57 to 1.20)
0.51 (0.34 to 0.78)
0.81 (0.71 to 0.93)
Study
Major cerebrovascular events
Favours
statin
Favours
control
No of patients/No of events
Odds ratio
(95% CI)
Odds ratio
(95% CI)
3293/51
3301/17
1654/62
5185/231
5137/212
1410/39
946/29
3966/62
8901/64
33 793/767
Statin
group
3302/46
3304/14
1585/61
5170/209
5168/166
1428/21
959/27
3866/50
8901/33
33 683/627
Control
group
1.09 (0.84 to 1.43)
0.97 (0.81 to 1.16)
1.03 (0.89 to 1.19)
0.65 (0.37 to 1.16)
0.97 (0.75 to 1.25)
0.89 (0.77 to 1.04)
0.97 (0.89 to 1.05)
0.25 0.5 1 2
Study
Cancer 
Favours
statin
Favours
control
No of patients/No of events
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Statin
group
Control
group
WOSCOPS
w9
AFCAPS/TexCapsw8
ALLHAT-LLT
w7
CARDS
w4
MEGA
w2
JUPITER
w1
Total
  Q statistic P=0.61, I2=0%*
3293/49
3301/259
5185/369
1410/30
3966/126
8901/372
26 056/1205
3302/44
3304/252
5170/378
1428/20
3866/119
8901/333
25 971/1146
Fig 2 | Odds ratios (95% confidence intervals) for all cause mortality, major coronary events, major cerebrovascular events, and incidence of cancer. (Mortality
risk based on mean follow-up of 4.1 years, with data from nine trials, and 67476 patients free of cardiovascular disease (no data available from HPS diabetic
arm
w5). Risk of coronary events based on mean follow-up of 4.9 years, with data from eight trials, and 50681 patients free of cardiovascular disease (no data
available from ASPEN
w3 and JUPITER
w1). Risk of cerebrovascular events based on mean follow-up of 4.1 years, with data from nine trials, and 67476 patients
free of cardiovascular disease (no data available from HPS diabetic arm). Risk of cancer based on mean follow-up of 3.9 years, with data from six trials, and
52027 patients free of cardiovascular disease (no data available from HPS, ASCOT,
w10 PROSPER,
w6 and ASPEN). See footnote to table 1 for full titles of studies.
*Measures of heterogeneity
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vascular events with placebo in our study was 0.6%
(fig2).Theannualrateforcoronaryheartdiseasemor-
tality with placebo in our study was 0.3%, for non-fatal
myocardialinfarctionitwas0.6%,forrevascularisation
it was 0.6%, and for incidence of cancer it was 1.2%.
Theassociationbetweenstatintherapyandriskofcan-
cer was not significant (0.97, 0.89 to 1.05; fig 2 and
table 2). Table 2 also shows the summary odds ratios
for other end points.
The outcome of the analyses was not influenced by
removal of the three trials that enrolled 4445 patients
(6%) with a previous cardiovascular event (all cause
mortality odds ratio 0.87, 95% confidence interval
0.78 to 0.97). Also, using only the first reported data
from ASCOT-LLA instead of the extended follow-up
data that were published later did not influence the
result of the analyses (0.88, 0.81 to 0.97).
w10 When the
only study (Justification for the Use of Statins in Pre-
vention: an Intervention Trial Evaluating Rosuvasta-
tin; JUPITER)
w1 that found a significant effect on
mortality was removed from the analysis, the reduc-
tion in mortality in the other nine trials remained sig-
nificant (0.89, 0.81 to 0.97).
No funnel plot asymmetry was visualised for the
main end points, and P values using the Egger regres-
sion test were greater than 0.10 for all the major end
points (all cause mortality: intercept −0.8, 95% confi-
dence interval −3.1 to 1.5; P value 0.42).
Subgroup analyses
No heterogeneity in treatment effect was observed for
end points in men and women and for age (≤65 and
>65 years) or diabetic status (fig 3).
DISCUSSION
The current meta-analysis totalled 70388 participants
without established cardiovascular disease but with
cardiovascular risk factors who were randomised to
statintherapyorcontrol.Statintherapywasassociated
withasignificantriskreductioninallcausemortalityof
12%, in major coronary events of 30%, and in major
cerebrovascular events of 19%. Moreover, statin use
was not associated with an increased risk of cancer.
These results are in line with those previously pub-
lished on the effects of statins in secondary
prevention.
56
Our meta-analysis differs from earlier analyses in
several ways.
1314 We were able to include several
recently published studies targeted at primary preven-
tionthatenrolledalargenumberofwomenandpeople
with diabetes.
w1-w3 For example, the Management of
Elevated Cholesterol in the Primary Prevention
Group of Adult Japanese trial (MEGA)
w2 comprised a
large number of women (68%, 5356/7832), and we
were able to obtain subgroup data. Additionally, the
Atorvastatin Study for Prevention of Coronary Heart
Disease Endpoints in Non-Insulin-Dependent Dia-
betes Mellitus study (ASPEN)
w3 was carried out in a
large group of people with type 2 diabetes (n=1905)
who did not have established cardiovascular disease.
We also included data from the recently published
JUPITER trial,
w1 totalling 17802 participants with no
apparentvasculardisease,lowdensitylipoproteincho-
lesterol levels less than 3.4 mmol/l, and increased
levels of high sensitivity C reactive protein
(>2.0mg/l).
w1Asourstudyisbasedonsuchlargenum-
bers, this meta-analysis, including the subgroups, has
significantstatistical power.Previously, only the JUPI-
TER trial showed improved survival associated with
Table 2 |Treatment effects of statin therapy. Values are odds ratios (95% confidence intervals)
Source All cause mortality
Major coronary
events
Major
cerebrovascular
events
Coronary heart
disease mortality
Non-fatal
myocardial
infarction Revascularisations
Fatal or non-fatal
cancer
WOSCOPS
w9 0.78 (0.60 to 1.01) 0.68 (0.56 to 0.83) 0.90 (0.60 to 1.34) 0.73 (0.48 to1.11) 0.69 (0.55 to 0.85) 0.63 (0.44 to 0.90) 1.09 (0.84 to 1.43)
AFCAPS/TexCAPS
w8 1.04 (0.76 to 1.43) 0.61 (0.45 to 0.83) 0.82 (0.40 to 1.67)* 0.73 (0.34 to 1.60) NR 0.69 (0.55 to 0.86) 0.97 (0.81 to 1.16)
PROSPER
w6 0.98 (0.79 to 1.21)* 0.90 (0.70 to 1.15) 1.03 (0.72 to 1.47) NR NR 0.82 (0.54 to 1.25)* NR†
ALLHAT-LLT
w7 0.99 (0.88 to 1.11) 0.90 (0.78 to 1.04) 0.90 (0.75 to 1.09) 0.99 (0.79 to 1.24) NR NR 1.03 (0.89 to 1.19)
ASCOT-LLA
w10 0.85 (0.73 to 0.97) 0.64 (0.52 to 0.78) 0.77 (0.63 to 0.95) NR NR NR NR
HPS
w5 NR 0.57 (0.41 to 0.79)* NR NR NR NR NR
CARDS
w4 0.72 (0.51 to 1.02) 0.65 (0.44 to 0.97) 0.52 (0.31 to 0.90) 0.74 (0.40 to 1.36) 0.59 (0.36 to 0.98) 0.69 (0.41 to 1.17) 0.65 (0.37 to 1.16)
ASPEN
w3 1.06 (0.69 to 1.64) NR 0.92 (0.54 to 1.56) NR NR 0.92 (0.60 to 1.40) NR
MEGA
w2 0.71 (0.50 to 1.00) 0.55 (0.33 to 0.91) 0.83 (0.57 to 1.20) 0.55 (0.22 to 1.38) 0.55 (0.30 to 1.00) 0.60 (0.40 to 0.90) 0.97 (0.75 to 1.25)
JUPITER
w1 0.80 (0.66 to 0.96) NR 0.51 (0.34 to 0.78) NR 0.35 (0.22 to 0.58) 0.54 (0.40 to 0.72) 0.89 (0.77 to 1.04)
All trials fixed effects
model
0.90 (0.84 to 0.96) 0.74 (0.68 to 0.81) 0.82 (0.74 to 0.91) 0.88 (0.73 to 1.05) 0.61 (0.52 to 0.73) 0.67 (0.59 to 0.76) 0.97 (0.89 to 1.05)
All trials random
effects model
0.88 (0.81 to 0.96) 0.70 (0.61 to 0.81) 0.81 (0.71 to 0.93) 0.88 (0.73 to 1.05) 0.56 (0.41 to 0.76) 0.67 (0.59 to 0.76) 0.97 (0.89 to 1.05)
Heterogeneity:
Q statistic 0.20 0.02‡ 0.23 0.49 0.11 0.48 0.61
I
2 index Low (27%) Moderate (60%) Low (24%) Low (0%) Moderate (50%) Low (0%) Low (0%)
NR=not reported. See footnote to table 1 for full titles of studies.
*Data from Thavendiranathan et al.
14 Fixed effect and random effect models in meta-analysis gave almost identical results, making important statistical heterogeneity unlikely.
†No data in primary prevention group (n=3239).
w6
‡Significant heterogeneity; however, a positive trend of statin therapy is observed in all trials, only of different magnitude (no neutral or negative trials).
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BMJ | ONLINE FIRST | bmj.com page 5 of 8statin use in high risk participants, but it is clear from
the current analysis that a mortality benefit is a shared
characteristic of long term statin use in people without
previous cardiovascular disease. The currently
observed benefit, a 12% risk reduction in mortality,
may even be an underestimation of the true effect
because subsequent death after a morbid cardio-
vasculareventwasnotalwaysconsideredinindividual
trials.
Thenumbersanddurationoffollow-upofourstudy
allow for relatively strong inferences on risk of cancer
withlongtermstatinuse.Wefoundnoevidenceforan
increased risk of cancer, fatal or non-fatal. One of the
trials(ProspectiveStudyofPravastatinintheElderlyat
Risk;PROSPER)
w6didreportanincreasedriskofcan-
cer with use of statins among men and women older
than 70. Although our results show that statins do not
seem to increase the risk of cancer, longer follow-up
would be helpful to determine whether new cancer
events could occur with time. This is especially critical
when statins are used in primary prevention. Follow-
upofpatientsinWOSCOPSfor10yearsdidnotshow
higher rates of malignancies.
3435 Concerns might
remain about the higher risk of cancer in elderly
patients (70-82 years) as in PROSPER,
w6 and further
follow-up studies in such patients are required.
Although this meta-analysis cannot fully remove that
uncertainty, it confirms that the risk of cancer is not
Sex
  Men
  Women
  P for heterogeneity = 0.62
Age
  <65
  >65
  P for heterogeneity = 0.57
Diabetes mellitus
  No
  Yes
  P for heterogeneity = 0.94
0.95 (0.86 to 1.06)
0.91 (0.76 to 1.08)
0.89 (0.74 to 1.04)
0.95 (0.80 to 1.12)
0.96 (0.76 to 1.21)
0.95 (0.84 to 1.07)
0.5 1 2
Subgroup
All cause mortality
Favours
statin
Favours
control
No of patients
Odds ratio
(95% CI)
Odds ratio
(95% CI)
13 413
10 372
12 889
10 896
16 672
3809
Statin
group
13 508
10 445
13 129
10 824
16 890
3762
Control
group
Sex
  Men
  Women
  P for heterogeneity = 0.65
Age
  <65
  >65
  P for heterogeneity = 0.11
Diabetes mellitus
  No
  Yes
  P for heterogeneity = 0.45
0.72 (0.61 to 0.86)
0.79 (0.56 to 1.13)
0.62 (0.42 to 0.87)
0.86 (0.67 to 1.09)
0.76 (0.57 to 1.01)
0.88 (0.69 to 1.13)
Subgroup
Favours
statin
Favours
control
No of patients
Odds ratio
(95% CI)
Odds ratio
(95% CI)
13 413
10 372
10 300
10 181
16 672
3809
Statin
group
13 508
10 445
10 529
10 123
16 890
3762
Control
group
Major coronary events
Major cerebrovascular events Cancer 
0.25 0.5 1 2
0.25 0.5 1 2
Sex
  Men
  Women
  P for heterogeneity = 0.90
Age
  <65
  >65
  P for heterogeneity = 0.37
Diabetes mellitus
  No
  Yes
  P for heterogeneity = 0.43
0.77 (0.44 to 1.36)
0.74 (0.54 to 1.00)
0.62 (0.42 to 0.89)
0.79 (0.53 to 1.18)
0.71 (0.48 to 1.04)
0.88 (0.60 to 1.28)
Subgroup
Favours
statin
Favours
control
No of patients
Odds ratio
(95% CI)
Odds ratio
(95% CI)
7949
7362
7989
7322
13 357
1954
Statin
group
8060
7407
8192
7275
13 488
1979
Control
group
Sex
  Men
  Women
  P for heterogeneity = 0.22
Age
  <65
  >65
  P for heterogeneity = 0.30
Diabetes mellitus
  No
  Yes
  P for heterogeneity = 0.24
0.95 (0.84 to 1.08)
1.09 (0.91 to 1.30)
0.92 (0.78 to 1.07)
1.05 (0.87 to 1.28)
0.99 (0.81 to 1.22)
1.34 (0.85 to 2.13)
Subgroup
Favours
statin
Favours
control
No of patients
Odds ratio
(95% CI)
Odds ratio
(95% CI)
10 754
7861
10 578
8037
13 357
1954
Statin
group
10 863
7905
10 792
7976
13 488
1979
Control
group
2 0.5 1 4
Fig 3 | Odds ratios (95% confidence intervals) for clinically defined subgroups of sex, age, and diabetes for end points of all
cause mortality, major coronary events, major cerebrovascular events, and cancer. Subgroup data are obtained from AFCAPS,
w8
PROSPER,
w6 ASPEN,
w3 MEGA,
w2 and JUPITER
w1, and for mortality and coronary events from ALLHAT-LLT.
w7 We had complete
mortality data from all six trials for sex; for age, no data from PROSPER on age<65; for diabetes, no data from ASPEN and
AFCAPS on participants without diabetes, and no data from AFCAPS and JUPITER on participants with diabetes. For
cardiovascular events, studies included in subgroup analysis were same as for mortality, except no data from AFCAPS for age
groups. For cerebrovascular disease, no data from AFCAPS and ALLHAT for all subgroups; also no data from PROSPER on age
<65, from ASPEN for participants without diabetes, and from JUPITER for participants with diabetes. For cancer no subgroup
data were obtained from ALLHAT; also no data for age <65 from PROSPER, for participants without diabetes from AFCAPS and
ASPEN, and for participants with diabetes from JUPITER and AFCAPS. See footnote to table 1 for full titles of studies
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is also important to tackle in primary prevention. Side
effects such as an increase in creatine kinase levels and
myopathy have been reported relatively frequently,
but rhabdomyolysis and hepatotoxicity are rare.
5
Lastly, by contacting principal investigators of each
trial we were able to obtain data on clinically defined
subgroups. This allowed us to draw meaningful infer-
encesontreatmenteffectsin largenumbersofwomen,
olderpeople,andpeoplewithdiabetes.Althoughthere
is little reason to suspect different treatment effects
betweensuchgroupsfromapathophysiologicalstand-
point, it is reassuring that no significant treatment het-
erogeneitywasfoundbetweenthesexes,inelderlyand
young people, and between people with and without
diabetes.
Limitations of the study
Some limitations of our study need to be mentioned.
Firstly,we includedthreetrialsintheanalysesthathad
recruited a small proportion of patients (about 6%)
with clinical cardiovascular disease.
30w7 w9 Exclusion
of these trials did not affect the outcome of our ana-
lyses. Secondly, the dose and type of statin differed
between included trials. Depending on the statin and
thedose,sometreatmentregimensmaybemoreeffec-
tive in lowering lipid levels. However, according to
guidelinesfromthe AdultTreatmentPanelIII,the sta-
tins included in our meta-analysis at their respective
doses have similar clinical efficacy.
8 Thirdly, the
included trials represented participants with a clini-
cally heterogeneous level of risk (although statistical
heterogeneity was low). The benefit observed in the
pooled estimate of treatment effect could be of differ-
ent magnitude depending on the level of risk. How-
ever, exclusion of the studies with a small proportion
ofpatientsathigherriskdidnotinfluencetheoutcome
oftheanalysisbecauseoursubgroupanalysisindicated
no heterogeneity in clinically defined groups such as
elderly participants or those with diabetes mellitus
whoareatrelativelyhigherrisk.Suchariskdependent
effect seems unlikely.
Clinical implications
Our meta-analysis shows that the relative risk reduc-
tion from long term statin use in a primary care setting
is comparable to that observed in secondary preven-
tion. Our findings confirm the results of JUPITER
w1
regarding the beneficial effect of statins on survival
across a broader range of patients (n=70388) at differ-
ent levels of risk, and show that there is no significant
difference in treatment benefit across a range of clini-
callydefinedgroups(menandwomen,elderlypeople,
and those with diabetes). Although our study popula-
tion comprised participants without established
cardiovascular disease, the pooled risk was high. The
overall annual mortality was in the range of 1.4%, and
fatal as well as non-fatal cardiac and cerebrovascular
events occurred at an annual rate of about 1.1% and
0.6%, respectively. This is not too different from the
event rates reported in trials of patients at relatively
low risk in secondary prevention—for example, the
Europeantrialonreductionofcardiaceventswithperi-
ndopril in stable coronary artery disease and the Pre-
vention of Events with Angiotensin-Converting
Enzyme inhibition trial (PEACE).
3637 Statin based sec-
ondary prevention is considered mandatory in partici-
pants in PEACE. Still, the absolute overall treatment
benefitobservedinthecurrentstudypopulationwould
certainly be less than 1%, and significant numbers of
participants would need to be treated to prevent one
event.Fromthe currentlypooleddata itisnot possible
to exactly define one group of people who would ben-
efit most from long term statin use. From current risk
scoringsystems,aswellfromcurrentdata,itisobvious
that older men (>65 years) with risk factors, or older
women with diabetes and risk factors, constitute the
highestriskgroup.Inviewofthelargetreatmenteffects
described here, it is likely that a considerable number
of such people would benefit from long term statin use
at reasonable costs. The correct identification of such
people remains a challenge and, in addition to the
assessment on the future cardiovascular risk based on
standardcardiovascularriskfactors,auxiliarydiagnos-
tic or prognostic assessments to improve risk predic-
tion could be useful to identify these men and women
more accurately. Given the favourable effects of long
term statin treatment it would be wrong to deny these
benefits to people at increased risk for cardiovascular
disease.
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